BioSpace News Archive

Cambridge Orthopaedic Labs, the creator of the first patented non-invasive external fracture fixation system, PolyArmour, announces that the first commercial PolyArmour case was performed by Douglas Fugate, MD at Punxsutawney Area Hospital, PA on Friday April 28, 2023.

INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

Inhibikase Therapeutics, Inc. today announced that it will report financial results for the first quarter ended March 31, 2023, on Monday, May 15, 2023, after the close of U.S. markets.

Rallybio Corporation today announced that company management will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference on Monday, May 15 at 2:30 p.m. ET in New York, NY.

Cognito Therapeutics announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone on Cardiac Repolarization in a Thorough QT Study in Healthy Subjects.”

Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live – jslm) a first-in-class single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Scholar Rock announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab.

Bio-Rad Laboratories, Inc. today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).

ClearNote Health™, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the publication of its analytical validation study for the Avantect™ Pancreatic Cancer Test in Clinical Gastroenterology and Hepatology.